Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

47
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
47
Experimental RNAi02:15

Experimental RNAi

8.4K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

626
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
626
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

19.1K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

104
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
104

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoproteins act as vehicles for lipid antigen delivery and activation of invariant natural killer T cells.

JCI insight·2023
Same author

Discovery and replication of SNP-SNP interactions for quantitative lipid traits in over 60,000 individuals.

BioData mining·2017
Same author

Extending the use of GWAS data by combining data from different genetic platforms.

PloS one·2017
Same author

Not All Patients with Critical Limb Ischaemia Require Revascularisation.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2016
Same author

Adherence to guidelines to prevent cardiovascular diseases: The LifeLines cohort study.

The Netherlands journal of medicine·2015
Same author

Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis.

International journal of epidemiology·2015

Related Experiment Video

Updated: Apr 19, 2026

Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions
11:57

Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions

Published on: April 21, 2016

7.1K

ApoA-I mimetics.

R M Stoekenbroek1, E S Stroes, G K Hovingh

  • 1Department of Vascular Medicine, Academic Medical Center, 22660, 1100 DD, Amsterdam, The Netherlands.

Handbook of Experimental Pharmacology
|December 20, 2014
PubMed
Summary
This summary is machine-generated.

High-density lipoprotein cholesterol (HDL-C) levels do not always correlate with cardiovascular disease (CVD) risk reduction. Focus is shifting to improving HDL functionality, particularly apolipoprotein A-I (ApoA-I) mimetics, for better therapeutic outcomes.

More Related Videos

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
10:08

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain

Published on: August 28, 2012

12.4K
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

20.1K

Related Experiment Videos

Last Updated: Apr 19, 2026

Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions
11:57

Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions

Published on: April 21, 2016

7.1K
Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
10:08

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain

Published on: August 28, 2012

12.4K
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

20.1K

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Pharmacology

Background:

  • Plasma high-density lipoprotein cholesterol (HDL-C) levels are inversely associated with cardiovascular disease (CVD) risk.
  • Despite this, therapies targeting increased HDL-C levels have not consistently reduced CVD outcomes.
  • This necessitates a shift towards strategies that enhance HDL functionality.

Purpose of the Study:

  • To explore the role of apolipoprotein A-I (ApoA-I) in HDL's antiatherogenic functions.
  • To review therapies designed to mimic ApoA-I function, including ApoA-I mimetic peptides.
  • To assess the potential of ApoA-I mimetics in treating atherosclerosis and other conditions.

Main Methods:

  • Review of existing clinical trial data on HDL-C-raising therapies.
  • Analysis of the role of ApoA-I in reverse cholesterol transport (RCT).
  • Examination of ApoA-I mimetic peptides and their mechanisms of action.

Main Results:

  • Clinical trials targeting increased HDL-C levels have yielded disappointing results for CVD outcomes.
  • ApoA-I is crucial for HDL's antiatherogenic properties, including RCT.
  • ApoA-I mimetics show promise due to their ability to mimic ApoA-I function and potential anti-inflammatory effects.

Conclusions:

  • Therapeutic strategies should focus on improving HDL functionality rather than solely increasing HDL-C levels.
  • ApoA-I mimetics represent a promising therapeutic avenue for cardiovascular disease.
  • The anti-inflammatory properties of ApoA-I mimetics suggest broader therapeutic applications beyond atherosclerosis.